Literature DB >> 9884007

Medication use patterns among demented, cognitively impaired and cognitively intact community-dwelling elderly people.

K E Schmader1, J T Hanlon, G G Fillenbaum, M Huber, C Pieper, R Horner.   

Abstract

OBJECTIVE: To determine whether medication use patterns in community-dwelling elderly people vary with level of cognitive function-dementia, cognitive impairment (but not dementia) and intact cognition.
DESIGN: Cross-sectional survey.
SETTING: A five-county area of central North Carolina, USA. PARTICIPANTS: 520 members of the Duke Established Populations for Epidemiologic Studies of the Elderly. MEASUREMENTS: Medication use in the previous 2 weeks was ascertained during a interview in the patient's home and was coded as to prescription and therapeutic class status. Cognitive status, the primary independent variable, was divided into: (i) dementia (n=100); (ii) cognitive impairment but not dementia (n=117); and (iii) cognitively intact (n=303). The dependent variables were any prescription or over-the-counter (OTC) medication use (vs non-use); number of prescription or OTC medications used; and prescription and OTC use combined within major therapeutic classes. Multivariate analyses controlled for socio-demographic characteristics, health status, functional status and access to health care.
RESULTS: The use of any prescription medication was similar in the three groups. The demented were significantly less likely than cognitively impaired people to use any OTC medications (OR=0.65, 95% CI=0.45, 0.93), cardiovascular medications (OR=0.70, 95% CI=0.49, 0.99) and analgesics (OR=0.54, 95% CI=0.39, 0.75). As a combined group, those who were demented and cognitively impaired were less likely than the cognitively intact group to use any OTC medications (OR=0.78, 95% CI 0.65, 0.92). Compared with the cognitively impaired subjects, the demented group took fewer prescription medications (beta coefficient=-0.31, 95% CI=-0.59, -0.03) and similar numbers of OTC medications. Compared with those who were cognitively intact, the combined group of demented and cognitively impaired subjects took fewer OTC medications (beta coefficient=-0.14, 95% CI=-0.23, -0.05) and similar numbers of prescription medications.
CONCLUSION: Increasing level of cognitive dysfunction is associated with decreased use of OTC, cardiovascular and analgesic medications and the use of fewer prescription medications. These results suggest important differences in medication use patterns among community-dwelling elderly people who vary in cognitive status.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9884007     DOI: 10.1093/ageing/27.4.493

Source DB:  PubMed          Journal:  Age Ageing        ISSN: 0002-0729            Impact factor:   10.668


  19 in total

1.  The effect of dementia on medication use and adherence among Medicare beneficiaries with chronic heart failure.

Authors:  Gail B Rattinger; Sarah K Dutcher; Pankdeep T Chhabra; Christine S Franey; Linda Simoni-Wastila; Stephen S Gottlieb; Bruce Stuart; Ilene H Zuckerman
Journal:  Am J Geriatr Pharmacother       Date:  2012-01-20

2.  Mild cognitive impairment is common in Parkinson's disease patients with normal Mini-Mental State Examination (MMSE) scores.

Authors:  Eugenia Mamikonyan; Paul J Moberg; Andrew Siderowf; John E Duda; Tom Ten Have; Howard I Hurtig; Matthew B Stern; Daniel Weintraub
Journal:  Parkinsonism Relat Disord       Date:  2008-07-02       Impact factor: 4.891

3.  The use of angiotensin-converting enzyme inhibitors and other drugs with cardiovascular effects by non-demented and demented elderly with a clinical diagnosis of heart failure. A population-based study of the very old.

Authors:  Inga Klarin; Johan Fastbom; Anders Wimo
Journal:  Eur J Clin Pharmacol       Date:  2006-05-10       Impact factor: 2.953

Review 4.  Variability in the prescription of cardiovascular medications in older patients: correlates and potential explanations.

Authors:  Cinzia Maraldi; Fabrizia Lattanzio; Graziano Onder; Massimo Gallerani; Silvia Bustacchini; Giuseppe De Tommaso; Stefano Volpato
Journal:  Drugs Aging       Date:  2009-12       Impact factor: 3.923

5.  Montreal cognitive assessment performance in patients with Parkinson's disease with "normal" global cognition according to mini-mental state examination score.

Authors:  Sarra Nazem; Andrew D Siderowf; John E Duda; Tom Ten Have; Amy Colcher; Stacy S Horn; Paul J Moberg; Jayne R Wilkinson; Howard I Hurtig; Matthew B Stern; Daniel Weintraub
Journal:  J Am Geriatr Soc       Date:  2008-12-10       Impact factor: 5.562

Review 6.  Drug use in patients with dementia: a register-based study in the health region of Girona (Catalonia/Spain).

Authors:  Pilar Avila-Castells; Josep Garre-Olmo; Laia Calvó-Perxas; Oriol Turró-Garriga; Elisabet Alsina; Olga Carmona; Héctor Perkal; Anna Maria Roig; Josep Ma Cuy; Manuela Lozano; Albert Molins; Natàlia Vallmajó; Secundino López-Pousa
Journal:  Eur J Clin Pharmacol       Date:  2012-11-23       Impact factor: 2.953

Review 7.  Adherence to medication in patients with dementia: predictors and strategies for improvement.

Authors:  Sönke Arlt; Reinhard Lindner; Alexander Rösler; Wolfgang von Renteln-Kruse
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

8.  Persistent use of analgesic medications in mild-to-moderate Alzheimer's disease.

Authors:  Adeline Gallini; Virginie Gardette; Bruno Vellas; Maryse Lapeyre-Mestre; Sandrine Andrieu; Christine Brefel-Courbon
Journal:  Drugs Aging       Date:  2013-06       Impact factor: 3.923

9.  Cognitive Impairment and Medication Complexity in Community-Living Older Adults: The Health, Aging and Body Composition Study.

Authors:  David Sh Lee; Nathalie de Rekeneire; Joseph T Hanlon; Thomas M Gill; Douglas C Bauer; Bernd Meibohm; Tamara B Harris; Sean M Jeffery
Journal:  J Pharm Technol       Date:  2012-07-01

10.  Depressive symptoms are associated with analgesic use in people with Alzheimer's disease: Kuopio ALSOVA study.

Authors:  Julia Fiona-Maree Gilmartin; Saku Väätäinen; Soili Törmälehto; J Simon Bell; Eija Lönnroos; Lotta Salo; Ilona Hallikainen; Janne Martikainen; Anne M Koivisto
Journal:  PLoS One       Date:  2015-02-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.